These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30154359)

  • 21. Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy.
    Lok AS; Sulkowski MS; Kort JJ; Willner I; Reddy KR; Shiffman ML; Hassan MA; Pearlman BL; Hinestrosa F; Jacobson IM; Morelli G; Peter JA; Vainorius M; Michael LC; Fried MW; Wang GP; Lu W; Larsen L; Nelson DR
    Gastroenterology; 2019 Dec; 157(6):1506-1517.e1. PubMed ID: 31401140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
    Wang GP; Schnell GL; Kort JJ; Sidhu GS; Schuster L; Tripathi RL; Larsen L; Michael LC; Bergquist K; Magee A; Patel CB; Whitlock JA; Tamashiro R; Peter JA; Fried MW; Nelson DR
    J Hepatol; 2021 Oct; 75(4):820-828. PubMed ID: 34023351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice.
    Teraoka Y; Uchida T; Imamura M; Osawa M; Tsuge M; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K;
    Biochem Biophys Res Commun; 2018 Jun; 500(2):152-157. PubMed ID: 29621544
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.
    Lin CW; Dutta S; Ding B; Wang T; Zadeikis N; Asatryan A; Kort J; Campbell A; Podsadecki T; Liu W
    J Clin Pharmacol; 2017 Dec; 57(12):1616-1624. PubMed ID: 28800195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
    Jensen SB; Fahnøe U; Pham LV; Serre SBN; Tang Q; Ghanem L; Pedersen MS; Ramirez S; Humes D; Pihl AF; Filskov J; Sølund CS; Dietz J; Fourati S; Pawlotsky JM; Sarrazin C; Weis N; Schønning K; Krarup H; Bukh J; Gottwein JM
    Hepatology; 2019 Sep; 70(3):771-787. PubMed ID: 30964552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
    Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ
    Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Durability of sustained virological response to glecaprevir/pibrentasvir and resistance development: A long-term follow-up study.
    Poordad F; Felizarta F; Yao BB; Overcash JS; Hassanein T; Agarwal K; Gane E; Shaw D; Waters M; Krishnan P; Topp A; Burroughs M; Nevens F
    Liver Int; 2022 Jun; 42(6):1278-1286. PubMed ID: 35220658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
    Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.
    Ramirez S; Fernandez-Antunez C; Mikkelsen LS; Pedersen J; Li YP; Bukh J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31818814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts.
    Forns X; Feld JJ; Dylla DE; Pol S; Chayama K; Hou J; Heo J; Lampertico P; Brown A; Bondin M; Tatsch F; Burroughs M; Marcinak J; Zhang Z; Emmett A; Gordon SC; Jacobson IM
    Adv Ther; 2021 Jun; 38(6):3409-3426. PubMed ID: 34021887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older.
    Huff J; Andersen R
    Ann Pharmacother; 2020 Mar; 54(3):262-276. PubMed ID: 31537106
    [No Abstract]   [Full Text] [Related]  

  • 32. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
    Cotter TG; Jensen DM
    Drug Des Devel Ther; 2019; 13():2565-2577. PubMed ID: 31534310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
    Lawitz EJ; O'Riordan WD; Asatryan A; Freilich BL; Box TD; Overcash JS; Lovell S; Ng TI; Liu W; Campbell A; Lin CW; Yao B; Kort J
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1546-55. PubMed ID: 26711747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection.
    Zuckerman E; Gutierrez JA; Dylla DE; de Ledinghen V; Muir AJ; Gschwantler M; Puoti M; Caruntu F; Slim J; Nevens F; Sigal S; Cohen S; Fredrick LM; Pires Dos Santos AG; Rodrigues L; Dillon JF
    Clin Gastroenterol Hepatol; 2020 Oct; 18(11):2544-2553.e6. PubMed ID: 32621971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterisation of a Hepatitis C Virus Subtype 2a Cluster in Scottish PWID with a Suboptimal Response to Glecaprevir/Pibrentasvir Treatment.
    Shah R; Barclay ST; Peters ES; Fox R; Gunson R; Bradley-Stewart A; Shepherd SJ; MacLean A; Tong L; van Vliet VJE; Ngan Chiu Bong M; Filipe A; Thomson EC; Davis C
    Viruses; 2022 Jul; 14(8):. PubMed ID: 36016300
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
    Poordad F; Felizarta F; Asatryan A; Sulkowski MS; Reindollar RW; Landis CS; Gordon SC; Flamm SL; Fried MW; Bernstein DE; Lin CW; Liu R; Lovell SS; Ng TI; Kort J; Mensa FJ
    Hepatology; 2017 Aug; 66(2):389-397. PubMed ID: 28128852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV-infected Japanese Subjects in Phase 3 CERTAIN-1 and CERTAIN-2 Trials.
    Suleiman AA; Lin CW; Liu W; Eckert D; Mensing S; Burroughs M; Kato K; Chayama K; Kumada H; Oberoi RK
    J Clin Pharmacol; 2020 Mar; 60(3):331-339. PubMed ID: 31515816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection.
    Reau N; Kwo PY; Rhee S; Brown RS; Agarwal K; Angus P; Gane E; Kao JH; Mantry PS; Mutimer D; Reddy KR; Tran TT; Hu YB; Gulati A; Krishnan P; Dumas EO; Porcalla A; Shulman NS; Liu W; Samanta S; Trinh R; Forns X
    Hepatology; 2018 Oct; 68(4):1298-1307. PubMed ID: 29672891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic Infection with Hepatitis C Virus Subtype 1g in a Japanese Patient Successfully Treated with Glecaprevir/Pibrentasvir.
    Hatanaka T; Kakizaki S; Kaburagi T; Saito N; Nakano S; Hazama Y; Yoshida S; Hachisu Y; Tanaka Y; Yoshinaga T; Kashiwabara K; Naganuma A; Yamazaki Y; Uraoka T; Nagashima S; Takahashi M; Nishizawa T; Murata K; Okamoto H
    Intern Med; 2022 May; 61(10):1537-1543. PubMed ID: 34897154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures.
    Osawa M; Imamura M; Teraoka Y; Uchida T; Morio K; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Aikata H; Hayes CN; Chayama K;
    J Gastroenterol; 2019 Mar; 54(3):291-296. PubMed ID: 30334096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.